Results 1 to 1 of 1 matches
Category 6 - PATHOLOGY SERVICES
73351 - Additional Information
Item Start Date:
01-Feb-2019
Description Updated:
01-Feb-2019
Schedule Fee Updated:
01-Feb-2019
Group
P7 - Genetics
A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.
Fee: $397.35 Benefit: 75% = $298.05 85% = $337.75
Results 1 to 1 of 1 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change